Airway epithelial regeneration (autologous basal cells)

Class

Cell therapy

The airway lining is a pseudostratified epithelium built from several cell types—ciliated cells that move mucus, secretory cells that produce it, and basal cells that sit beneath them and act as the tissue's resident stem cell population. Basal cells self-renew and differentiate to replace epithelium lost to injury, infection, or chronic inflammation. When this regenerative capacity is overwhelmed or genetically impaired, the airway surface can become denuded, remodeled, or functionally abnormal, contributing to conditions such as chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis, and radiation- or toxin-induced airway injury. An autologous basal cell therapy approach isolates a patient's own basal cells, expands them outside the body, and reintroduces them—typically by direct bronchoscopic delivery—to damaged regions with the goal of reconstituting a functional, mucociliary-competent epithelium. Because the cells originate from the patient, this strategy is intended to minimize immune rejection compared with donor-derived or engineered cell products. The broader rationale is structural and functional restoration of a barrier and clearance system rather than modulation of a single receptor or enzyme, distinguishing this class of therapy from conventional small-molecule or biologic pharmacology. Its relevance spans any chronic airway disease where epithelial exhaustion or damage, rather than a single molecular driver, underlies disease progression.